We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+22.63%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$321M
AUM Growth
+$7.85M
Cap. Flow
-$56.6M
Cap. Flow %
-17.66%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
OPGN
OpGen, Inc
OPGN
+$209K

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$56.8M

Sector Composition

Rank Sector Weight
1 Healthcare 93.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.64B
$212M 66.16%
3,608,874
-997,368
-22% -$56.8M
BOLD
2
DELISTED
Audentes Therapeutics, Inc
BOLD
$46M 14.36%
1,204,615
– –
OCUL icon
3
Ocular Therapeutix
OCUL
$1.85B
$15M 4.67%
2,215,384
– –
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$14.1M 4.39%
1,048,601
– –
AKAO
5
DELISTED
Achaogen Inc
AKAO
$11.1M 3.46%
1,281,152
– –
IMDZ
6
DELISTED
Immune Design Corp.
IMDZ
$10M 3.13%
2,208,210
– –
VANI icon
7
Vivani Medical
VANI
$111M
$7.46M 2.33%
187,207
– –
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$4.63M 1.44%
101,855
– –
OPGN
9
DELISTED
OpGen, Inc
OPGN
$182K 0.06%
+26
New +$209K

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q2 2018 Portfolio in Review

As of Q2 2018, Versant Venture Management held 9 positions worth $321M, up 2.5% from $313M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $56.6M in Q2 2018, reducing 1 holding. Its largest reduction was CRISPR Therapeutics, cutting an estimated $56.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

Against the trend, Versant Venture Management opened a new position in OpGen, Inc worth $182K.

  • Versant Venture Management's largest Q2 2018 buy was OpGen, Inc: 26 shares worth $182K.
  • Versant Venture Management's biggest Q2 2018 reduction was CRISPR Therapeutics, cutting an estimated $56.8M.
  • Versant Venture Management's ten largest holdings make up 100% of its $321M portfolio in Q2 2018.
  • Versant Venture Management opened 1 new position and closed 0 in Q2 2018.
  • Versant Venture Management's portfolio value rose 2.5% quarter-over-quarter to $321M.

Based on Versant Venture Management's 13F filing for Q2 2018, filed 13 Jul 2018.